WES has determined that there is a minimal frequency of pathogenetic variants (approximately three variants per tumor) in children that are under the age of 5 years with hepatoblastoma (HB) [49,50,51], while in the first case of hepatocellular carcinoma (HCC), a high mutational degree and the coexistence of pathogenic variants in CTNNB1 (Catenin Beta 1) and NFE2L2 (NFE2 Like BZIP Transcription Factor 2) were detected by a WES analysis [52]. This evidence concerns the gene NFE2L2 and hepatoblastoma.